ICVX Stock Price, Icosavax, Inc. Quote, Chart

Market Summary

USD15.31

Market Closed

ICVX Stock Price

View Fullscreen

ICVX RSI Chart

ICVX Valuation

Market Cap

766.9M

Price/Earnings (Trailing)

-7.93

Price/Sales (Trailing)

1.3K

Price/Free Cashflow

-10.05

ICVX Price/Sales (Trailing)

ICVX Profitability

Return on Equity

-41.62%

Return on Assets

-38.49%

Free Cashflow Yield

-9.95%

ICVX Fundamentals

ICVX Revenue

Revenue (TTM)

582.0K

ICVX Earnings

Earnings (TTM)

-96.7M

Earnings Growth (Yr)

-0.3%

Earnings Growth (Qtr)

16.82%

Breaking Down ICVX Revenue

Last 30 days

0.1%

Last 90 days

45.8%

Trailing 12 Months

87.2%

How does ICVX drawdown profile look like?

ICVX Financial Health

Current Ratio

18.06

ICVX Investor Care

Shares Dilution (1Y)

25.54%

Diluted EPS (TTM)

-2.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	6.4M	4.5M	2.7M	582.0K
2021	3.2M	4.7M	6.3M	7.8M
2020	0	0	0	1.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Icosavax, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 19, 2024	shiver john w.	sold	-	-	-8,066	-
Feb 19, 2024	simpson adam k.	sold	-	-	-654,076	-
Feb 19, 2024	mcdade mark	sold	-	-	-55,786	-
Feb 19, 2024	fields heidi	sold	-	-	-11,376	-
Feb 19, 2024	shiver john w.	back to issuer	-	-	-2,833	-
Feb 19, 2024	mcdade mark	sold	-	-	-3,510,230	-
Feb 19, 2024	veneman ann m	sold	-	-	-11,209	-
Feb 19, 2024	veneman ann m	back to issuer	-	-	-2,834	-
Feb 19, 2024	russo thomas joseph	sold	-	-	-39,367	-
Feb 19, 2024	fields heidi	back to issuer	-	-	-2,917	-

Which funds bought or sold ICVX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-10,000	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-1,463,080	-	-%
Apr 23, 2024	AMALGAMATED BANK	sold off	-100	-33,000	-	-%
Apr 22, 2024	Vivo Capital, LLC	sold off	-100	-26,864,000	-	-%
Apr 22, 2024	MetLife Investment Management, LLC	added	18.59	138,920	237,330	-%
Apr 19, 2024	Cutler Group LLC / CA	sold off	-100	-7,000	-	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	sold off	-100	-294,838	-	-%
Apr 11, 2024	Fortitude Family Office, LLC	sold off	-100	-8,810	-	-%
Apr 09, 2024	SYQUANT CAPITAL SAS	sold off	-100	-3,005,000	-	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-3.59	14,130,000	28,841,700	-%

Are Funds Buying or Selling ICVX?

Are funds buying ICVX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ICVX

No. of Funds

Unveiling Icosavax, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 21, 2024	qiming u.s. healthcare gp ii, llc	0.0%	0	SC 13D/A
Feb 21, 2024	ra capital management, l.p.	0%	0	SC 13D/A
Feb 14, 2024	t. rowe price investment management, inc.	7.8%	3,926,407	SC 13G
Feb 14, 2024	pentwater capital management lp	5.9%	3e+06	SC 13G
Feb 14, 2024	citadel advisors llc	0.5%	6	SC 13G/A
Feb 12, 2024	platinum investment management ltd	-	0	SC 13G
Feb 07, 2024	blackrock inc.	4.9%	2,467,810	SC 13G/A
Feb 02, 2024	blackrock inc.	5.2%	2,581,530	SC 13G
Jan 10, 2024	fmr llc	-	0	SC 13G/A
Nov 24, 2023	adams street partners llc	4.2%	2,095,087	SC 13D/A

Recent SEC filings of Icosavax, Inc.

View All Filings

Date Filed	Form Type	Document
Mar 01, 2024	15-12G	15-12G
Feb 21, 2024	SC 13D/A	13D - Major Acquisition
Feb 21, 2024	SC 13D/A	13D - Major Acquisition
Feb 21, 2024	SC TO-T/A	SC TO-T/A
Feb 20, 2024	4	Insider Trading
Feb 20, 2024	4	Insider Trading
Feb 20, 2024	4	Insider Trading
Feb 20, 2024	4	Insider Trading
Feb 20, 2024	4	Insider Trading
Feb 20, 2024	4	Insider Trading

Peers (Alternatives to Icosavax, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Icosavax, Inc. News

Latest updates

Icosavax, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)									(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	-	-	-	-	582,000	2,070,000	1,827,000	1,904,000	2,001,000	-
Operating Expenses	8.6%	25,131,000	23,143,000	23,131,000	24,235,000	20,281,000	36,240,000	10,498,000	6,644,000	-
S&GA Expenses	16.7%	8,938,000	7,659,000	7,311,000	6,322,000	6,218,000	25,357,000	2,221,000	1,091,000	-
R&D Expenses	4.6%	16,193,000	15,484,000	15,820,000	17,913,000	14,063,000	10,883,000	8,277,000	5,553,000	-
Interest Expenses	-	-	-	-	120,000	-	-	-	-	-
Net Income	-7.4%	-23,613,000	-21,976,000	-22,636,000	-23,533,000	-18,182,000	-34,386,000	-8,552,000	-5,851,000	-4,608,000
Net Income Margin	-384.3%	-157	-32.55	-22.04	-13.26	-8.58	-8.54	-5.22	-6.71	-11.67
Free Cashflow	33.5%	-14,183,000	-21,333,000	-18,690,000	-18,582,000	-13,459,000	-9,341,000	-12,430,000	-4,316,000	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-6.6%	251	269	220	239	244	260	277	288	301	119	16.00
Current Assets	-6.5%	235	252	202	224	229	249	270	287	300	116	16.00
Cash Equivalents	-59.2%	63.00	155	50.00	60.00	66.00	109	262	281	294	112	15.00
Net PPE	-6.0%	11.00	12.00	12.00	12.00	12.00	8.00	3.00	1.00	1.00	1.00	0.00
Liabilities	-11.2%	19.00	21.00	20.00	21.00	18.00	17.00	17.00	9.00	8.00	6.00	13.00
Current Liabilities	-13.2%	13.00	15.00	13.00	14.00	13.00	12.00	14.00	9.00	8.00	6.00	6.00
Shareholder's Equity	-6.2%	232	248	200	218	226	242	260	278	292	-	-
Retained Earnings	-9.3%	-258	-236	-210	-185	-162	-140	-117	-94.07	-75.89	-41.50	-27.10
Additional Paid-In Capital	1.4%	491	485	411	404	388	383	377	372	368	2.00	0.00
Shares Outstanding	0.3%	50.00	50.00	41.00	41.00	40.00	40.00	39.00	39.00	26.00	3.00	3.00

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	1.3%	-18,972	-19,222	-21,649	-11,633	-17,378	-15,204	-17,460	-13,036	-9,326	-11,996	-4,182	-	-	-
Share Based Compensation	4.6%	6,602	6,311	6,000	6,158	5,434	5,552	4,550	3,677	23,670	1,408	276	-	-	-
Cashflow From Investing	-230.2%	-72,654	55,822	12,027	-4,113	-26,183	-138,031	-1,122	-423	-15.00	-434	-134	-	-	-
Cashflow From Financing	-100.3%	-208	68,071	117	10,087	-279	223	276	260	191,500	-767	113,779	-	-	-

ICVX Income Statement

2023-09-30

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Grant revenue	$ 0	$ 0	$ 0	$ 582
Operating expenses:
Research And Development Expenses	16,668	15,484	53,851	49,217
General and administrative	8,607	7,659	26,901	21,292
Total operating expenses	25,275	23,143	80,752	70,509
Loss from operations	(25,275)	(23,143)	(80,752)	(69,927)
Other income (expense):
Interest and other	3,234	1,167	7,653	1,782
Total other income	3,234	1,167	7,653	1,782
Net loss	(22,041)	(21,976)	(73,099)	(68,145)
Comprehensive loss:
Unrealized losses on available-for-sale debt securities	18	(334)	355	(609)
Comprehensive loss	$ (22,023)	$ (22,310)	$ (72,744)	$ (68,754)
Net loss per share, basic	$ (0.44)	$ (0.55)	$ (1.61)	$ (1.72)
Net loss per share, diluted	$ (0.44)	$ (0.55)	$ (1.61)	$ (1.72)
Weighted-average common shares outstanding, basic	50,030,759	39,748,984	45,411,654	39,623,357
Weighted-average common shares outstanding, diluted	50,030,759	39,748,984	45,411,654	39,623,357

ICVX Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 63,239	$ 58,846
Restricted cash	0	1,061
Short-term investments	165,967	159,461
Prepaid expenses and other current assets	6,101	4,545
Total current assets	235,307	223,913
ROU assets - operating leases	2,975	3,247
Property and equipment, net	11,400	11,517
Other Assets Noncurrent	1,614	0
Total assets	251,296	238,677
Current liabilities:
Accounts payable	1,239	2,892
Accrued and other current liabilities	9,606	8,759
Current portion of operating lease liabilities	2,185	2,137
Total current liabilities	13,030	13,788
Lease liabilities, net of current portion	5,886	6,658
Other noncurrent liabilities	0	69
Total liabilities	18,916	20,515
Commitments and contingencies (Note 2)
Stockholders' equity
Common stock, $0.0001 par value; 500,000,000 shares authorized at September 30, 2023 and December 31, 2022; 50,088,633 and 41,177,706 shares issued as of September 30, 2023 and December 31, 2022, respectively; 50,088,633 and 41,095,564 shares outstanding as of September 30, 2023 and December 31, 2022, respectively	7	6
Additional paid-in capital	491,347	404,386
Accumulated other comprehensive loss	(48)	(403)
Accumulated deficit	(258,926)	(185,827)
Total stockholders' equity	232,380	218,162
Total liabilities and stockholders' equity	$ 251,296	$ 238,677

About Icosavax, Inc.

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington.

CEO	Mr. Adam K. Simpson
WEBSITE	https://icosavax.com
INDUSTRY	Biotechnology
EMPLOYEES	60

Icosavax, Inc. Frequently Asked Questions

What is the ticker symbol for Icosavax, Inc.? What does ICVX stand for in stocks?

ICVX is the stock ticker symbol of Icosavax, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Icosavax, Inc. (ICVX)?

As of Thu Feb 29 2024, market cap of Icosavax, Inc. is 766.88 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ICVX stock?

You can check ICVX's fair value in chart for subscribers.

What is the fair value of ICVX stock?

You can check ICVX's fair value in chart for subscribers. The fair value of Icosavax, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Icosavax, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ICVX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Icosavax, Inc. a good stock to buy?

The fair value guage provides a quick view whether ICVX is over valued or under valued. Whether Icosavax, Inc. is cheap or expensive depends on the assumptions which impact Icosavax, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ICVX.

What is Icosavax, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 29 2024, ICVX's PE ratio (Price to Earnings) is -7.93 and Price to Sales (PS) ratio is 1.32 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ICVX PE ratio will change depending on the future growth rate expectations of investors.